27. Investments in subsidiaries

As of

31 March 2025

$m

31 March 2024

$m

1 Includes share of goodwill of $18m (March 2024: $19m).

Assets

Non-current assets

578

520

Current assets

59

64

Liabilities

Non-current liabilities

290

250

Current liabilities

196

191

Equity

151

143

% of ownership interest held by NCI

49%

49%

Accumulated NCI1

92

89

For the year ended

31 March 2025

$m

31 March 2024

$m

Revenue

322

309

Net profit

14

18

Other comprehensive loss

(4)

(16)

Total comprehensive income

9

2

Profit allocated to NCI

7

9

For the year ended

31 March 2025

$m

31 March 2024

$m

Net cash inflow from operating activities

136

122

Net cash outflow from investing activities

(90)

(83)

Net cash outflow from financing activities

(49)

(41)

Net cash outflow

(3)

(2)

  

Dividend paid to NCI during the year (included in cash flow from financing activities)

4

6

As of

31 March 20251

$m

31 March 2024

$m

1 Includes hyperinflationary impact on adoption of IAS 29.

2 includes share of goodwill of $112m (March 2024: $20m).

Assets

Non-current assets

204

115

Current assets

71

47

Liabilities

Non-current liabilities

88

64

Current liabilities

110

106

Equity

77

(8)

% of ownership interest held by NCI

20%

20%

Accumulated NCI2

128

18

For the year ended

31 March 20251

$m

31 March 2024

$m

1 Includes hyperinflationary impact on adoption of IAS 29.

Revenue

172

164

Net profit/(loss)

33

(9)

Other comprehensive income/(loss)

49

(8)

Total comprehensive income/(loss)

82

(17)

Profit/(loss) allocated to NCI

7

(2)

For the year ended

31 March 2025

$m

31 March 2024

$m

Net cash inflow from operating activities

65

89

Net cash outflow from investing activities

(14)

(77)

Net cash outflow from financing activities

(22)

(24)

Net cash inflow/(outflow)

29

(12)

  

Dividend paid to NCI during the year (included in cash flow from financing activities)

0

5

As of

31 March 2025

$m

31 March 2024

$m

1 The NCI in AMCBV of 22.11% (March 2024: 22.11%) excludes the NCI of $6m (March 2024: $7m) in the subsidiaries within the AMCBV group (i.e. Tanzania, Niger and the Republic of the Congo).

Assets

Non-current assets

80

52

Current assets

1,434

1,086

Liabilities

Non-current liabilities

31

23

Current liabilities

1,092

894

Equity

391

220

% of ownership interest held by NCI1

22%

22%

Accumulated NCI1

85

47

For the year ended

31 March 2025

$m

31 March 2024

$m

Revenue

990

806

Net profit

305

248

Other comprehensive income/(loss)

13

(19)

Total comprehensive income

318

229

Profit allocated to NCI

66

55

For the year ended

31 March 2025

$m

31 March 2024

$m

Net cash inflow from operating activities

596

482

Net cash inflow from investing activities

(49)

102

Net cash outflow from financing activities

(195)

(174)

Net cash inflow

352

410

  

Dividend paid to NCI during the year (included in cash flow from financing activities)

56

51